TAVO 101
Alternative Names: TAVO-101Latest Information Update: 19 Apr 2024
At a glance
- Originator Tavotek Biotherapeutics
- Class Antiallergics; Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Thymic stromal lymphopoietin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Hypersensitivity
Most Recent Events
- 15 Mar 2024 Phase-II clinical trials in Atopic dermatitis in New Zealand (IV) (NCT06176040)
- 19 Dec 2023 Tavotek Biotherapeutics plans a phase II trial for Atopic Dermatitis (IV, Infusion)
- 11 May 2022 Phase-I clinical trials in Hypersensitivity (In volunteers) in Australia (IV) (NCT05298046)